Reuters logo
BRIEF-Novartis submits application to FDA for Kymriah™ (tisagenlecleucel) in adult patients with R/R DLBCL
October 31, 2017 / 11:44 AM / 18 days ago

BRIEF-Novartis submits application to FDA for Kymriah™ (tisagenlecleucel) in adult patients with R/R DLBCL

Oct 31 (Reuters) - Novartis AG

* Novartis submits application to FDA for Kymriah™ (Tisagenlecleucel) in adult patients with R/R DLBCL, seeking second indication for first-ever FDA approved Car-T therapy

* Novartis AG - ‍plans to submit additional application for marketing authorization for Kymriah with EMA in DLBCL and pediatric all later this year​

* ‍plans additional regulatory filings for Kymriah outside US and EU in 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below